JP2022541539A5 - - Google Patents
Info
- Publication number
- JP2022541539A5 JP2022541539A5 JP2022503414A JP2022503414A JP2022541539A5 JP 2022541539 A5 JP2022541539 A5 JP 2022541539A5 JP 2022503414 A JP2022503414 A JP 2022503414A JP 2022503414 A JP2022503414 A JP 2022503414A JP 2022541539 A5 JP2022541539 A5 JP 2022541539A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2019-0085233 | 2019-07-15 | ||
| KR20190085233 | 2019-07-15 | ||
| PCT/KR2020/009207 WO2021010712A1 (ko) | 2019-07-15 | 2020-07-13 | 항-타우 항체 및 이의 용도 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022541539A JP2022541539A (ja) | 2022-09-26 |
| JP2022541539A5 true JP2022541539A5 (https=) | 2023-07-24 |
| JP7595061B2 JP7595061B2 (ja) | 2024-12-05 |
Family
ID=74088428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022503414A Active JP7595061B2 (ja) | 2019-07-15 | 2020-07-13 | 抗タウ抗体およびその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220204601A1 (https=) |
| EP (1) | EP4001305A4 (https=) |
| JP (1) | JP7595061B2 (https=) |
| KR (1) | KR102196840B1 (https=) |
| CN (1) | CN114430744B (https=) |
| AU (1) | AU2020313751A1 (https=) |
| BR (1) | BR112022000719A2 (https=) |
| CA (1) | CA3143811A1 (https=) |
| CL (1) | CL2022000087A1 (https=) |
| GB (1) | GB2600599B (https=) |
| IL (1) | IL289813A (https=) |
| MX (1) | MX2022000603A (https=) |
| MY (1) | MY207132A (https=) |
| PH (1) | PH12022550106A1 (https=) |
| TW (1) | TW202116801A (https=) |
| WO (1) | WO2021010712A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10501531B2 (en) | 2013-03-13 | 2019-12-10 | Prothena Biosciences Limited | Tau immunotherapy |
| MY198194A (en) | 2016-05-02 | 2023-08-09 | Prothena Biosciences Ltd | Antibodies Recognizing Tau |
| PT3452507T (pt) | 2016-05-02 | 2022-12-20 | Prothena Biosciences Ltd | Imunoterapia anti-tau |
| KR102784294B1 (ko) | 2017-05-02 | 2025-03-19 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
| JP7630834B2 (ja) | 2019-03-03 | 2025-02-18 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
| US20240376188A1 (en) * | 2021-09-09 | 2024-11-14 | The University Of North Carolina At Chapel Hill | Monoclonal antibodies targeting acetylated tau and methods of use thereof |
| US20250134952A1 (en) | 2021-09-20 | 2025-05-01 | Institut National de la Santé et de la Recherche Médicale | Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor |
| WO2023229445A1 (ko) * | 2022-05-27 | 2023-11-30 | 주식회사 진큐어 | 신규 펩타이드 및 그의 용도 |
| CN115724967A (zh) * | 2022-09-21 | 2023-03-03 | 天津鸿宇泰生物科技有限公司 | 一种识别Tau蛋白N端区域的单克隆抗体及其应用 |
| EP4631975A1 (en) | 2022-12-08 | 2025-10-15 | Adel Inc. | Fusion comprising anti-tau antibody and peptide and use thereof |
| WO2024133723A1 (en) | 2022-12-22 | 2024-06-27 | Institut National de la Santé et de la Recherche Médicale | Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy |
| CN116716352A (zh) * | 2023-05-16 | 2023-09-08 | 深圳湾实验室 | Tau蛋白聚集的细胞模型、其构建方法及应用 |
| CN116693682B (zh) * | 2023-06-02 | 2024-04-19 | 涌源合生科技(深圳)有限公司 | 抗Tau蛋白抗体及其制备方法和用途 |
| CN116948025B (zh) * | 2023-09-14 | 2024-04-02 | 北京凯祥弘康生物科技有限公司 | 一种抗Tau蛋白的抗体 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130251731A1 (en) * | 2012-03-22 | 2013-09-26 | The Trustees Of The University Of Pennsylvania | Tau Acetylation in the Pathogenesis of Alzheimers Disease and Other Related Tauopathies |
| RU2644242C2 (ru) * | 2012-04-05 | 2018-02-08 | Ац Иммуне С.А. | Гуманизированное тау-антитело |
| SG10201708959WA (en) | 2012-07-03 | 2017-11-29 | Univ Washington | Antibodies to tau |
| TWI734975B (zh) * | 2014-06-27 | 2021-08-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| TWI669314B (zh) * | 2015-02-26 | 2019-08-21 | 美國禮來大藥廠 | 針對ｔａｕ之抗體及其用途 |
| WO2018106889A1 (en) * | 2016-12-09 | 2018-06-14 | Cogwellin L.L.C. | Diagnosis of alzheimer's disease |
| KR102032314B1 (ko) * | 2016-12-21 | 2019-10-16 | 주식회사 아델 | 변이된 타우 단백질 단편 및 이의 용도 |
-
2020
- 2020-07-13 EP EP20841174.4A patent/EP4001305A4/en active Pending
- 2020-07-13 CN CN202080063893.8A patent/CN114430744B/zh active Active
- 2020-07-13 MY MYPI2022000234A patent/MY207132A/en unknown
- 2020-07-13 KR KR1020200086341A patent/KR102196840B1/ko active Active
- 2020-07-13 JP JP2022503414A patent/JP7595061B2/ja active Active
- 2020-07-13 GB GB2201160.5A patent/GB2600599B/en active Active
- 2020-07-13 WO PCT/KR2020/009207 patent/WO2021010712A1/ko not_active Ceased
- 2020-07-13 BR BR112022000719A patent/BR112022000719A2/pt unknown
- 2020-07-13 CA CA3143811A patent/CA3143811A1/en active Pending
- 2020-07-13 MX MX2022000603A patent/MX2022000603A/es unknown
- 2020-07-13 AU AU2020313751A patent/AU2020313751A1/en active Pending
- 2020-07-13 PH PH1/2022/550106A patent/PH12022550106A1/en unknown
- 2020-07-15 TW TW109123934A patent/TW202116801A/zh unknown
-
2022
- 2022-01-12 CL CL2022000087A patent/CL2022000087A1/es unknown
- 2022-01-12 IL IL289813A patent/IL289813A/en unknown
- 2022-01-12 US US17/574,227 patent/US20220204601A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022541539A5 (https=) | ||
| CN110799531B (zh) | 抗PHF-tau抗体及其用途 | |
| CN102089430B (zh) | 针对渐进性糖化终极产物受体(rage)的抗体及其用途 | |
| AU2013211874B2 (en) | Humanized antibodies that recognize alpha-synuclein | |
| EP2603523B1 (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| JP2014502150A5 (https=) | ||
| JP2018519810A5 (https=) | ||
| CA2494008A1 (en) | Anti-myelin associated glycoprotein (mag) antibodies | |
| JP7109467B2 (ja) | タウに特異的に結合する結合分子 | |
| NZ748983A (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| JP2019528083A5 (https=) | ||
| US10633435B2 (en) | Anti-PHF-tau antibodies and uses thereof | |
| JP2020513791A5 (https=) | ||
| JP2019527194A5 (https=) | ||
| WO2013039954A1 (en) | Anti-gitr antibodies | |
| IL266911B2 (en) | Anti-tau antibodies and uses thereof in treating tauopathy, retaining or increasing cognitive memory capacity or slowing memory loss | |
| JP2021530960A5 (https=) | ||
| JP2018505651A5 (https=) | ||
| US20250171557A1 (en) | Therapeutic agent for neurodegenerative disorder | |
| JP2017523805A5 (https=) | ||
| JP2014502276A5 (https=) | ||
| JP2023535024A5 (https=) | ||
| JP2023554382A5 (https=) | ||
| JP2023533768A5 (https=) | ||
| JP2023504209A5 (https=) |